Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release

Details for Australian Patent Application No. 2005324132 (hide)

Owner Bayer Schering Pharma Aktiengesellschaft

Inventors Henck, Jan-Olav; Benke, Klaus

Agent Davies Collison Cave

Pub. Number AU-B-2005324132

PCT Pub. Number WO2006/072367

Priority 10 2004 062 475.5 24.12.04 DE

Filing date 13 December 2005

Wipo publication date 13 July 2006

Acceptance publication date 28 April 2011

International Classifications

A61K 31/5377 (2006.01)

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 9/28 (2006.01) Medicinal preparations characterised by special physical form - Dragees

Event Publications

26 July 2007 PCT application entered the National Phase

  PCT publication WO2006/072367 Priority application(s): WO2006/072367

14 May 2009 Assignment before Grant

  Bayer HealthCare AG The application has been assigned to Bayer Schering Pharma Aktiengesellschaft 2006

28 April 2011 Application Accepted

  Published as AU-B-2005324132

25 August 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005324133-Probe for detecting nucleic acids

2005324127-(5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors